farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2021.087farmaec-629Research ArticleREVIEW ARTICLESОБЗОРНЫЕ ПУБЛИКАЦИИEconomic burden of chronic viral hepatitis CЭкономическое бремя хронического вирусного гепатита Сhttps://orcid.org/0000-0002-7972-5607ЯхинаР. А.YakhinaR. A.

Яхина Рената Азаматовна – аспирант

РИНЦ SPIN-код: 7257-2963 

ул. Заки Валиди, д. 32, Уфа 450076, Республика Башкортостан

Renata A. Yakhina – Postgraduate

RSCI SPIN-code: 7257-2963 

3 Lenin Str., Ufa 450008, Republic of Bashkortostan

https://orcid.org/0000-0001-9876-9202ЛакманИ. А.LakmanI. A.

Лакман Ирина Александровна – к.т.н., доцент

WoS ResearcherID: K-6878-2017

Scopus Author ID: 57192164952

РИНЦ SPIN-код: 4521-9097 

ул. Заки Валиди, д. 32, Уфа 450076, Республика Башкортостан

Irina A. Lakman – PhD (Eng.), Associate Professor

WoS ResearcherID: K-6878-2017

Scopus Author ID: 57192164952

RSCI SPIN-code: 4521-9097 

3 Lenin Str., Ufa 450008, Republic of Bashkortostan

lackmania@mail.ruhttps://orcid.org/0000-0002-1811-9320ВалишинД. А.ValishinD. A.

Валишин Дамир Асхатович – д.м.н., профессор, заведующий кафедрой инфекционных болезней с курсом дополнительного профессионального образования

Scopus Author ID: 6506590910

РИНЦ SPIN-код: 9582-5853 

ул. Ленина, д. 3, Уфа 450008, Республика Башкортостан

Damir A. Valishin – Dr. Med. Sc., Professor, Chief of Chair of Infectious Diseases with Additional Professional Education Course

Scopus Author ID: 6506590910

RSCI SPIN-code: 9582-5853 

32 Zaki Validi Str., Ufa 450076, Republic of Bashkortostan

https://orcid.org/0000-0002-7237-4306БахитоваР. Х.BakhitovaR. Kh.

Бахитова Раиля Хурматовна – д.э.н., доцент, заведующая кафедрой

WoS ResearcherID: J-6179-2017

РИНЦ SPIN-код: 8726-3237 

ул. Заки Валиди, д. 32, Уфа 450076, Республика Башкортостан

Railya Kh. Bakhitova – Dr. Econ. Sc., Associate Professor, Chief of Chair

WoS ResearcherID: J-6179-2017

RSCI SPIN-code: 8726-3237 

3 Lenin Str., Ufa 450008, Republic of Bashkortostan

Федеральное государственное бюджетное образовательное учреждение высшего образования «Башкирский государственный университет»РоссияBashkir State Medical UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияBashkir State UniversityRussian Federation202115012022144523536Copyright © Yakhina R.A., Lakman I.A., Valishin D.A., Bakhitova R.K., 20222022Яхина Р.А., Лакман И.А., Валишин Д.А., Бахитова Р.Х.Yakhina R.A., Lakman I.A., Valishin D.A., Bakhitova R.K.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/629

Background. The spread of chronic viral hepatitis C (CVHC) among the population entails significant costs for society, both direct, associated with the treatment of such patients, and indirect, associated with the shortfall in fiscal payments to the budget, due to the disability of this category of patients. Therefore, an important task remains to assess the global economic burden of the disease, taking into account the pathological conditions of the human body associated with it.Objective: to systematize studies of published sources devoted to assessing the global economic burden of chronic viral hepatitis C.Material and methods. A feature of the proposed review design is paying attention not only to the objects of assessment under study, but also to the instrumental (including mathematical) means of scenario assessment of the global burden. The study analyzed 29 sources published between 2014 and 2020 and dedicated to assessing and forecasting the global economic burden of CVHC both in individual countries and continents as a whole, and in individual regions of countries. The main criterion for the selection of studies was the availability of an estimate of the global burden of CVHC, taking into account the use of direct antiviral drugs for the treatment of hepatitis C. The search was conducted in PubMed/MEDLINE and eLibrary databases, and in the ResearchGate network.Results. Of the 29 analyzed sources, 40% of the works consider the burden for CVHC only of certain genotypes; in the overwhelming number of articles (80%), when assessing the burden, the distribution of patients by the degree of liver fibrosis is taken into account. In 50% of the studies reviewed, quality of life adjustment tools (QALY or DALY) were used to estimate the global economic burden. A third of the publications took into account both the direct costs of treating CVHC and indirect costs, including those associated with a shortfall in the contribution to the gross national product due to temporary or permanent disability of this category of patients.Conclusion. The analysis showed that interest in assessing the global burden of CVHC began to appear in recent years, when expensive directacting antivirals for the treatment appeared. This is explained by the emergence of a question about the cost of implementing a scenario in which by a certain year it will be possible to completely exclude the spread of the disease. The results of this work may be useful in conducting such studies, including the determining of their design and the use of modern mathematical modeling tools.

Актуальность. Распространение хронического вирусного гепатита С (ХВГС) среди населения влечет за собой значительные затраты для общества – как прямые, связанные с лечением, так и косвенные, связанные с недополучением фискальных платежей в бюджет из-за нетрудоспособности таких больных. Поэтому важной задачей остается оценка глобального экономического бремени заболевания с учетом ассоциированных с ним паталогических состояний организма человека.Цель: систематизация опубликованных исследований, посвященных оценке глобального экономического бремени хронического вирусного гепатита С.Материал и методы. Особенностью предложенного дизайна обзора является уделение внимания не только исследуемым объектам оценки, но и применяемым инструментальным (в т.ч. математическим) средствам сценарной оценки глобального бремени. Проведен анализ 29 источников, опубликованных в период с 2014 по 2020 гг. и посвященных оценке и прогнозу глобального экономического бремени ХВГС как в отдельных странах и на континентах в целом, так и в определенных регионах стран. Основным критерием отбора исследований было наличие оценки глобального бремени ХВГС с учетом использования для лечения гепатита С препаратов прямого противовирусного действия. Поиск осуществляли по базам PubMed/MEDLINE и eLibrary, а также в сети ResearchGate.Результаты. Из 29 проанализированных источников в 40% работ рассматривается бремя для ХГВС лишь определенных генотипов, в подавляющем количестве исследований (80%) при оценке бремени учитывается распределение больных по степени фиброза печени. В 50% рассмотренных публикаций использовались инструменты с поправкой бремени на качество жизни: QALY (англ. quality-adjusted life year) или DALY (англ. disability-adjusted life year). В 1/3 исследований учитывались как прямые издержки на лечение ХВГС, так и косвенные затраты, в т.ч. связанные с недополучением вклада в валовой национальный продукт за счет временной либо стойкой нетрудоспособности этой категории больных.Заключение. Анализ показал, что интерес к оценке глобального бремени ХВГС возник в последние годы, когда появились дорогостоящие препараты прямого противовирусного действия. Это объясняется возникновением вопроса о стоимости реализации сценария, при котором к определенному году полностью можно будет исключить распространение болезни. Результаты данной работы будут полезны в проведении подобных исследований, в т.ч. для определения их дизайна и применения современных инструментов математического моделирования.

глобальное бремя болезниэкономическое бремя болезнихронический вирусный гепатит Сglobal burden of diseaseeconomic burden of diseasechronic viral hepatitis CИсследование выполнено при финансовой поддержке гранта РФФИ «Комплексный подход для сценарного прогнозирования экономического бремени хронического вирусного гепатита С в регионах России» № 20-310-90044.The study was carried out with the financial support of the Russian Foundation for Basic Research grant “An integrated approach for scenario forecasting of the economic burden of chronic viral hepatitis C in the regions of Russia” No. 20-310-90044.ReferencesЛакман И.А., Галямов А.Ф., Валишин Д.А. Прогноз социальноэкономического бремени хронического вирусного гепатита С (1 генотипа) при реализации различных сценарных прогнозов его распространения в республике Башкортостан. Инфекционные болезни. 2016; 14 (3): 67–74. https://doi.org/10.20953/1729-9225-2016-3-67-74.Lakman I.A., Galyamov A.F., Valishin D.A. Forecast of the socioeconomic burden of chronic viral hepatitis C (genotype 1) in the implementation of various scenario forecasts of its spread in the Republic of Bashkortostan. Infectious Diseases. 2016; 14 (3): 67–74 (in Russ.). https://doi.org/10.20953/1729-9225-2016-3-67-74.Лысанов Ю.И., Шаманова Л.В. Вирусные гепатиты: распространенность и динамика заболеваемости. Сибирский медицинский журнал (Иркутск). 2011; 103 (4): 110–3.Lysanov Y.I., Shamanova L.V. Virus hepatites: prevalence and dynamics of morbidity. Siberian Medical Journal (Irkutsk). 2011; 103 (4): 110–3 (in Russ.).El Khoury A.C., Klimack W.K., Wallace C., Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012; 19 (3): 153–60. https://doi.org/10.1111/j.1365-2893.2011.01563.x.El Khoury A.C., Klimack W.K., Wallace C., Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012; 19 (3): 153–60. https://doi.org/10.1111/j.1365-2893.2011.01563.x.El Khoury A.C., Klimack W.K., Wallace C., Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ. 2012; 15 (5): 887–96. https://doi.org/10.3111/13696998.2012.681332.El Khoury A.C., Klimack W.K., Wallace C., Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ. 2012; 15 (5): 887–96. https://doi.org/10.3111/13696998.2012.681332.Luhnen M., Waffenschmidt S., Gerber-Grote A., Hanke G. Health economic evaluations of sofosbuvir for treatment of chronic hepatitis C: a systematic review. Appl Health Econ Health Policy. 2016; 14 (5): 527– 43. https://doi.org/10.1007/s40258-016-0253-2.Luhnen M., Waffenschmidt S., Gerber-Grote A., Hanke G. Health economic evaluations of sofosbuvir for treatment of chronic hepatitis C: a systematic review. Appl Health Econ Health Policy. 2016; 14 (5): 527– 43. https://doi.org/10.1007/s40258-016-0253-2.Pascual-Argente N., Puig-Junoy J., Llagostera-Punzano A. Nonhealthcare costs of hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol. 2018; 12 (1): 19–30. https://doi.org/10.1080/17474124.2017.1373016.Pascual-Argente N., Puig-Junoy J., Llagostera-Punzano A. Nonhealthcare costs of hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol. 2018; 12 (1): 19–30. https://doi.org/10.1080/17474124.2017.1373016.Яхина Р.А. Методика оценки глобального экономического бремени болезни. Экономика и управление: научно-практический журнал. 2020; 6: 222–5. https://doi.org/10.34773/EU.2020.6.46.Yakhina R.А. Methodology for assessing the global economic burden of disease. Economics and Management: Research and Practice Journal. 2020; 6: 222–5 (in Russ.). https://doi.org/10.34773/EU.2020.6.46.Pfeil A.M., Reich O., Guerra I.M., et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PLoS One. 2015; 10 (5): e0126984. https://doi.org/10.1371/journal.pone.0126984.Pfeil A.M., Reich O., Guerra I.M., et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PLoS One. 2015; 10 (5): e0126984. https://doi.org/10.1371/journal.pone.0126984.Rattay T., Dumont I.P., Heinzow H.S., Hutton D.W. Cost-effectiveness of access expansion to treatment of hepatitis C virus infection through primary care providers. Gastroenterology. 2017; 153 (6):1531–43.e2. https://doi.org/10.1053/j.gastro.2017.10.016.Rattay T., Dumont I.P., Heinzow H.S., Hutton D.W. Cost-effectiveness of access expansion to treatment of hepatitis C virus infection through primary care providers. Gastroenterology. 2017; 153 (6):1531–43.e2. https://doi.org/10.1053/j.gastro.2017.10.016.Younossi Z.M., Park H., Saab S., et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015; 41 (6): 544–63. https://doi.org/10.1111/apt.13081.Younossi Z.M., Park H., Saab S., et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015; 41 (6): 544–63. https://doi.org/10.1111/apt.13081.Saab S., Parisé H., Virabhak S., et al. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ. 2016; 19 (8): 795–805. https://doi.org/10.1080/13696998.2016.1176030.Saab S., Parisé H., Virabhak S., et al. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ. 2016; 19 (8): 795–805. https://doi.org/10.1080/13696998.2016.1176030.Linas B.P., Barter D.M., Morgan J.R., et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015; 162 (9): 619–29. https://doi.org/10.7326/M14-1313.Linas B.P., Barter D.M., Morgan J.R., et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015; 162 (9): 619–29. https://doi.org/10.7326/M14-1313.Chahal H.S., Marseille E.A., Tice J.A., et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med. 2016; 176 (1): 65–73. https://doi.org/10.1001/jamainternmed.2015.6011.Chahal H.S., Marseille E.A., Tice J.A., et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med. 2016; 176 (1): 65–73. https://doi.org/10.1001/jamainternmed.2015.6011.Traebert J., Fratoni K.R.B.P., Rosa L.C.D.D., et al. The burden of hepatitis C infection in a Southern Brazilian State. Rev Soc Bras Med Trop. 2018; 51 (5): 670–3. https://doi.org/10.1590/0037-8682-0098-2017.Traebert J., Fratoni K.R.B.P., Rosa L.C.D.D., et al. The burden of hepatitis C infection in a Southern Brazilian State. Rev Soc Bras Med Trop. 2018; 51 (5): 670–3. https://doi.org/10.1590/0037-8682-0098-2017.Cure S., Guerra I., Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat. 2015; 22 (11): 882–9. https://doi.org/10.1111/jvh.12409.Cure S., Guerra I., Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat. 2015; 22 (11): 882–9. https://doi.org/10.1111/jvh.12409.Cure S., Guerra I., Cammà C., et al. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. J Med Econ. 2015; 18 (9): 678–90. https://doi.org/10.3111/13696998.2015.1040024.Cure S., Guerra I., Cammà C., et al. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. J Med Econ. 2015; 18 (9): 678–90. https://doi.org/10.3111/13696998.2015.1040024.Liu S., Watcha D., Holodniy M., Goldhaber-Fiebert J.D. Sofosbuvirbased treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014; 161 (8): 546–53. https://doi.org/10.7326/M14-0602.Liu S., Watcha D., Holodniy M., Goldhaber-Fiebert J.D. Sofosbuvirbased treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014; 161 (8): 546–53. https://doi.org/10.7326/M14-0602.Saab S., Virabhak S., Parisé H., et al. Cost-effectiveness of genotype 1 chronic hepatitis C virus treatments in patients coinfected with human immunodeficiency virus in the United States. Adv Ther. 2016; 33 (8): 1316–30. https://doi.org/10.1007/s12325-016-0362-1.Saab S., Virabhak S., Parisé H., et al. Cost-effectiveness of genotype 1 chronic hepatitis C virus treatments in patients coinfected with human immunodeficiency virus in the United States. Adv Ther. 2016; 33 (8): 1316–30. https://doi.org/10.1007/s12325-016-0362-1.Lu Y.C., Ross-Degnan D., Zhang F., et al. Cost burden of hepatitis C virus treatment in commercially insured patients. Am J Manag Care. 2019; 25 (12): 379–87.Lu Y.C., Ross-Degnan D., Zhang F., et al. Cost burden of hepatitis C virus treatment in commercially insured patients. Am J Manag Care. 2019; 25 (12): 379–87.Sicras-Mainar A., Navarro-Artieda R., Sáez-Zafra M. Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain. Gastroenterol Hepatol. 2018; 41 (4): 234–44. https://doi.org/10.1016/j.gastrohep.2017.11.008.Sicras-Mainar A., Navarro-Artieda R., Sáez-Zafra M. Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain. Gastroenterol Hepatol. 2018; 41 (4): 234–44. https://doi.org/10.1016/j.gastrohep.2017.11.008.Roebuck M.C., Liberman J.N. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid. Am J Manag Care. 2019; 25 (8 Suppl.): S131–9.Roebuck M.C., Liberman J.N. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid. Am J Manag Care. 2019; 25 (8 Suppl.): S131–9.Gissel C., Götz G., Mahlich J., Repp H. Cost-effectiveness of interferon-free therapy for hepatitis C in Germany – an application of the efficiency frontier approach. BMC Infect Dis. 2015; 15: 297. https://doi.org/10.1186/s12879-015-1048-z.Gissel C., Götz G., Mahlich J., Repp H. Cost-effectiveness of interferon-free therapy for hepatitis C in Germany – an application of the efficiency frontier approach. BMC Infect Dis. 2015; 15: 297. https://doi.org/10.1186/s12879-015-1048-z.Chhatwal J., Kanwal F., Roberts M.S., Dunn M.A. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015; 162 (6): 397–406. https://doi.org/10.7326/M14-1336.Chhatwal J., Kanwal F., Roberts M.S., Dunn M.A. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015; 162 (6): 397–406. https://doi.org/10.7326/M14-1336.Lim A.G., Walker J.G., Mafirakureva N., et al. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. Lancet Glob Health. 2020; 8 (3): e440– 50. https://doi.org/10.1016/S2214-109X(20)30003-6.Lim A.G., Walker J.G., Mafirakureva N., et al. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. Lancet Glob Health. 2020; 8 (3): e440– 50. https://doi.org/10.1016/S2214-109X(20)30003-6.Myers R.P., Krajden M., Bilodeau M., et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014; 28 (5): 243–50. https://doi.org/10.1155/2014/317623.Myers R.P., Krajden M., Bilodeau M., et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014; 28 (5): 243–50. https://doi.org/10.1155/2014/317623.Blach S., Schaetti C., Bruggmann P., et al. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. Swiss Med Wkly. 2019; 149: w20026. https://doi.org/10.4414/smw.2019.20026.Blach S., Schaetti C., Bruggmann P., et al. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. Swiss Med Wkly. 2019; 149: w20026. https://doi.org/10.4414/smw.2019.20026.Müllhaupt B., Bruggmann P., Bihl F., et al. Modeling the health and economic burden of hepatitis C virus in Switzerland. PLoS One. 2015; 10 (6): e0125214. https://doi.org/10.1371/journal.pone.0125214.Müllhaupt B., Bruggmann P., Bihl F., et al. Modeling the health and economic burden of hepatitis C virus in Switzerland. PLoS One. 2015; 10 (6): e0125214. https://doi.org/10.1371/journal.pone.0125214.Estes C., Abdel-Kareem M., Abdel-Razek W., et al. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther. 2015; 42 (6): 696–706. https://doi.org/10.1111/apt.13316.Estes C., Abdel-Kareem M., Abdel-Razek W., et al. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther. 2015; 42 (6): 696–706. https://doi.org/10.1111/apt.13316.Örmeci N., Malhan S., Balık İ., et al. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. Hepatol Int. 2017; 11 (6): 509–16. https://doi.org/10.1007/s12072-017-9820-3.Örmeci N., Malhan S., Balık İ., et al. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. Hepatol Int. 2017; 11 (6): 509–16. https://doi.org/10.1007/s12072-017-9820-3.Stepanova M., Younossi Z.M. Economic burden of hepatitis C infection. Clin Liver Dis. 2017; 21 (3): 579–94. https://doi.org/10.1016/j.cld.2017.03.012.Stepanova M., Younossi Z.M. Economic burden of hepatitis C infection. Clin Liver Dis. 2017; 21 (3): 579–94. https://doi.org/10.1016/j.cld.2017.03.012.Soipe A., Ravazi-Shearer D., Galárraga O., et al. Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination. Epidemiol Infect. 2016; 144 (16): 3376–86. https://doi.org/10.1017/S0950268816001722.Soipe A., Ravazi-Shearer D., Galárraga O., et al. Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination. Epidemiol Infect. 2016; 144 (16): 3376–86. https://doi.org/10.1017/S0950268816001722.Ющук Н.Д., Знойко О.О., Якушечкина Н.А. и др. Оценка социально-экономического бремени гепатита C в Российской Федерации. Эпидемиология и вакцинопрофилактика. 2013; 2: 18–33.Yuschuk N.D., Znoyko O.O., Yakushechkina N.A., et al. Assessment of the socio-economic burden of hepatitis C in the Russian Federation. Epidemiology and Vaccinal Prevention. 2013; 2: 18–33 (in Russ.).Никитин И.Г., Попович Л.Д., Потапчик Е.Г. Экономическое бремя хронического гепатита C в России. Эпидемиология и инфекционные болезни. Актуальные вопросы. 2015; 6: 9–13.Nikitin I.G., Popovich L.D., Potapchik E.G. The economic burden of chronic hepatitis C in Russia. Epidemiology and Infectious Diseases. Current Items. 2015; 6: 9–13 (in Russ.).Gandjour A. Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: a reanalysis of published results. PLoS One. 2020; 15 (10): e0236543. https://doi.org/10.1371/journal.pone.0236543.Gandjour A. Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: a reanalysis of published results. PLoS One. 2020; 15 (10): e0236543. https://doi.org/10.1371/journal.pone.0236543.

The authors declare that there are no conflicts of interest present.